<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053794</url>
  </required_header>
  <id_info>
    <org_study_id>I155</org_study_id>
    <secondary_id>CAN-NCIC-IND155</secondary_id>
    <secondary_id>CDR0000269476</secondary_id>
    <nct_id>NCT00053794</nct_id>
  </id_info>
  <brief_title>Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma</brief_title>
  <official_title>A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who&#xD;
      have metastatic or locally advanced soft tissue sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of perifosine, in terms of response rate and duration of&#xD;
           response, in patients with untreated metastatic or locally advanced soft tissue sarcoma.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the early progression rate in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a non-randomized, non-blinded, multicenter study.&#xD;
&#xD;
      Patients receive a loading dose of oral perifosine twice on day 1 and then once daily on days&#xD;
      2-21 for the first course. For all subsequent courses, patients receive a loading dose of&#xD;
      oral perifosine once on day 1 and then once daily on days 2-21. Courses repeat every 28 days&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for 1 month. Patients with stable or responsive disease are followed&#xD;
      every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 12-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2003</start_date>
  <completion_date type="Actual">September 22, 2008</completion_date>
  <primary_completion_date type="Actual">September 18, 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">17</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perifosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic or locally advanced soft tissue sarcoma that is&#xD;
             incurable by standard therapies, including any of the following types:&#xD;
&#xD;
               -  Uterine sarcomas&#xD;
&#xD;
                    -  Mixed mesodermal&#xD;
&#xD;
                    -  Leiomyosarcoma&#xD;
&#xD;
                    -  Endometrial stromal sarcoma&#xD;
&#xD;
               -  Alveolar soft part sarcoma&#xD;
&#xD;
               -  Angiosarcoma/lymphangiosarcoma&#xD;
&#xD;
               -  Fibrosarcoma&#xD;
&#xD;
               -  Hemangiopericytoma&#xD;
&#xD;
               -  Leiomyosarcoma&#xD;
&#xD;
               -  Liposarcoma&#xD;
&#xD;
               -  Malignant fibrous histiocytoma&#xD;
&#xD;
               -  Neurogenic sarcoma&#xD;
&#xD;
               -  Pleomorphic rhabdomyosarcoma&#xD;
&#xD;
               -  Synovial sarcoma&#xD;
&#xD;
               -  Unclassifiable sarcoma&#xD;
&#xD;
               -  Undifferentiated sarcoma&#xD;
&#xD;
          -  Excluded diseases include the following:&#xD;
&#xD;
               -  Bone sarcomas (e.g., osteosarcoma, Ewing's sarcoma, chondrosarcoma)&#xD;
&#xD;
               -  Embryonal rhabdomyosarcoma&#xD;
&#xD;
               -  Carcinosarcoma&#xD;
&#xD;
               -  Kaposi's sarcoma&#xD;
&#xD;
               -  Malignant mesothelioma&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  Gastrointestinal stromal tumor&#xD;
&#xD;
          -  At least 1 unidimensionally measurable site of disease (outside the previously&#xD;
             irradiated area) defined as:&#xD;
&#xD;
               -  At least 20 mm by x-ray or physical exam&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  At least 20 mm by non-spiral CT scan NOTE: Bone lesions are not considered&#xD;
                  measurable&#xD;
&#xD;
        NOTE: Patients whose sole site of disease is within a previously irradiated area are&#xD;
        allowed if there is evidence of progression or new lesions in the irradiated field&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biological&#xD;
             composition to perifosine&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated nonmelanoma skin&#xD;
             cancer or curatively treated carcinoma in situ of the cervix&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior systemic chemotherapy for metastatic or locally advanced disease&#xD;
&#xD;
          -  At least 6 months since prior adjuvant chemotherapy&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy (except low-dose, non-myelosuppressive&#xD;
             radiotherapy)&#xD;
&#xD;
          -  No concurrent radiotherapy to the sole site of measurable disease or for progressively&#xD;
             symptomatic disease&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent anticancer therapy or investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth A. Eisenhauer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Centre of Southeastern Ontario at Kingston General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Center - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Island Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital - Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve-Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs. 2006 Sep;24(5):435-9.</citation>
    <PMID>16528479</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult alveolar soft-part sarcoma</keyword>
  <keyword>adult angiosarcoma</keyword>
  <keyword>adult fibrosarcoma</keyword>
  <keyword>adult leiomyosarcoma</keyword>
  <keyword>adult liposarcoma</keyword>
  <keyword>adult synovial sarcoma</keyword>
  <keyword>endometrial stromal sarcoma</keyword>
  <keyword>uterine leiomyosarcoma</keyword>
  <keyword>adult malignant hemangiopericytoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>adult malignant fibrous histiocytoma</keyword>
  <keyword>adult neurofibrosarcoma</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

